Phosphodiesterase 3A1 protects the heart against angiotensin ii-induced cardiac remodeling through regulation of transforming growth factor-β expression

International Heart Journal

Volumn 55, Issue 2, 2014, Pages 165-168

  Iwaya, Shoji ^a   Oikawa, Masayoshi ^a   Chen, Yan ^b   Takeishi, Yasuchika ^a  

^a FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Cardiac fibrosis

Indexed keywords

ALPHA TUBULIN; ANGIOTENSIN II; PHOSPHODIESTERASE III; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; GENE OVEREXPRESSION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RATE; HEART SIZE; HEART WEIGHT; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS REGULATION; SYSTOLIC BLOOD PRESSURE; WESTERN BLOTTING;

ANGIOTENSIN II; ANIMALS; BLOTTING, WESTERN; CARDIOMYOPATHY, HYPERTROPHIC; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; DISEASE MODELS, ANIMAL; ECHOCARDIOGRAPHY; HEART VENTRICLES; MICE; MICE, TRANSGENIC; TRANSFORMING GROWTH FACTOR BETA; VASOCONSTRICTOR AGENTS; VENTRICULAR REMODELING;

EID: 84897059273     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.13-268     Document Type: Article

References (22)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348: 2007-18. (Review)
2. Barki-Harrington L, Luttrell LM, Rockman HA. Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo. Circulation 2003; 108: 1611-8.
3. Zhang GX, Ohmori K, Nagai Y, et al. Role of AT1 receptor in isoproterenol- induced cardiac hypertrophy and oxidative stress in mice. J Mol Cell Cardiol 2007; 42: 804-11.
4. Miller CL, Yan C. Targeting cyclic nucleotide phosphodiesterase in the heart: therapeutic implications. J Cardiovasc Transl Res 2010; 3: 507-15. (Review)
5. Fischmeister R, Castro LR, Abi-Gerges A, et al. Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 2006; 99: 816-28. (Review)
6. Oikawa M, Wu M, Lim S, et al. Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol 2013; 64: 11-9.
7. Leask A. Potential therapeutic targets for cardiac fibrosis: TGF beta, angiotensin, endothelin, CCN2, and PDGF, partners in fibroblast activation. Circ Res 2010; 106: 1675-80. (Review)
8. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004; 63: 423-32. (Review)
9. Deten A, Hölzl A, Leicht M, Barth W, Zimmer HG. Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J Mol Cell Cardiol 2001; 33: 1191-207.
10. Li JM, Brooks G. Differential protein expression and subcellular distribution of TGFβ1, β2 and β3 in cardiomyocytes during pressure overload-induced hypertrophy. J Mol Cell Cardiol 1997; 29: 2213-24.
11. Li RK, Li G, Mickle DA, et al. Overexpression of transforming growth factor-beta1 and insulin-like growth factor-I in patients with idiopathic hypertrophic cardiomyopathy. Circulation 1997; 96: 874-81.
12. Felkin LE, Lara-Pezzi E, George R, Yacoub MH, Birks EJ, Barton PJ. Expression of extracellular matrix genes during myocardial recovery from heart failure after left ventricular assist device support. J Heart Lung Transpl 2009; 28: 117-22.
13. Rosenkranz S, Flesch M, Amann K, et al. Alterations of betaadrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). Am J Physiol Heart Circ Physiol 2002; 283: H1253-62.
14. Schlüter KD, Zhou XJ, Piper HM. Induction of hypertrophic responsiveness to isoproterenol by TGF-β in adult rat cardiomyocytes. Am J Physiol 1995; 269: C1311-6.
15. Schlüter KD, Frischkopf K, Flesch M, Rosenkranz S, Taimor G, Piper HM. Central role for ornithine decarboxylase in β-adrenorceptor mediated hypertrophy. Cardiovasc Res 2000; 45: 410-7.
16. Ding B, Abe J, Wei H, et al. Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation 2005; 111: 2469-76.
17. Wenzel S, Taimor G, Piper HM, Schlüter KD. Redox-sensitive intermediates mediate angiotensin II-induced p38 MAP kinase activation, AP-1 binding activity, and TGF-beta expression in adult ventricular cardiomyocytes. FASEB J 2001; 15: 2291-3.
18. Ding B, Abe J, Wei H, et al. A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc Natl Acad Sci USA 2005; 102: 14771-6.
19. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488- 520. (Review)
20. Miller CL, Oikawa M, Cai Y, et al. Role of Ca2+/calmodulinstimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. Circ Res 2009; 105: 956-64.
21. Qvigstad E, Moltzau LR, Aronsen JM, et al. Natriuretic peptides increase β1-adrenoceptor signaling in failing hearts through phosphodiesterase 3 inhibition. Cardiovasc Res 2010; 85: 763-72.
22. Lehnart SE, Wehrens XH, Reiken S, et al. Phosphodiesterase 4D defi ciency in the ryanodine-receptor complex promotes heart failure and arrhythmias. Cell 2005; 123: 25-35.